ADMA Biologics ADMA 深 滬
等待開盤 11-04 09:30:00 美东时间
11.11
+0.050
+0.45%
華盛通- 最 高11.435
- 今 開11.09
- 成交量 505.58万股
- 最 低 10.695
- 昨 收 11.06
- 總市值 248.85万
- 52周最高 20.458
- 市盈率 靜 18.52
- 換手率 2.26%
- 52周最低 7.2101
- 委 比 59.22%
- 總股本 0.00亿
- 歷史最高 25.67
- 量 比 1.95
- 振 幅 6.69%
- 歷史最低 1.01
- 每 手 1
- 風險率 3.95%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多ADMA Biologics Inc收跌3.07%，成交额3248.22万美元
11月3日，ADMA Biologics Inc（ADMA）收跌3.07%，报11.06美元，成交额3248.22万美元，市值24.77亿美元。 行情数据 •...
11-03 06:20
ADMA Biologics to Report Third Quarter 2026 Financial Results on November 4, 2026
ADMA Biologics, a U.S.-based biopharmaceutical company, will report its third quarter 2026 financial results on November 4, 2026, followed by a live conference call at 4:30 p.m. ET. The call requires registration in advance, and an archived replay will be available on the company’s website. ADMA specializes in manufacturing and developing specialty biologics for immunodeficient patients, with approved products including ASCENIV™, BIVIGAM®, and NA...
10-28 11:00
ADMA Biologics Inc收涨3.6%，成交额2231.2万美元
10月27日，ADMA Biologics Inc（ADMA）收涨3.6%，报11.06美元，成交额2231.2万美元，市值24.78亿美元。 行情数据 • 开...
10-27 05:21
ADMA Biologics Inc收跌0.47%，成交额3283.23万美元
10月20-22日上海黄浦江畔，2026可持续全球领导者大会再度来袭。诺奖、图灵奖得主现场讲述科技未来与趋势，更有“解救”焦虑、内卷时代的网红教授——麦克法兰与...
10-17 05:24
ADMA Biologics shares are trading higher after the company announced the publication of a peer-reviewed article in Frontiers in Cardiovascular Medicine detailing new data from the company’s optimized, proprietary intravenous immune globulin manufacturing process.
ADMA Biologics shares are trading higher after the company announced the publication of a peer-reviewed article in Frontiers in Cardiovascular Medicine detailing new data from the company’s optimized, proprietary intravenous immune globulin manufacturing process.
10-15 22:20
ADMA Biologics Announces Peer-Reviewed Publication Highlighting New Data From Its Optimized, Proprietary IVIG Manufacturing Process
ADMA Biologics announced the publication of a study detailing improvements in their IVIG manufacturing process, which effectively removes procoagulant impurities while maintaining immunoglobulin quality and increasing IgG yield. No thromboembolic events were reported for ADMA IVIG products during the postmarketing surveillance period. The optimized process enhances patient safety and product quality, supporting ADMA's commitment to advancing biop...
10-15 11:00
ADMA Biologics Leans on ASCENIV in Earnings Call
ADMA Biologics Inc (($ADMA)) has held its Q2 earnings call. Read on for the mai...
08-21 08:24
ADMA Biologics (ADMA) Receives a Buy from Canaccord Genuity
In a report released today, Gary Nachman from Canaccord Genuity maintained a Bu...
08-06 19:18
财报速睇 | ADMA Biologics 2026财年Q2营收1.24亿美元，同比增长2.0%；归母净利润0.38亿美元，同比增长10.5%
华盛资讯8月6日讯，ADMA Biologics公布2026财年Q2业绩，公司Q2营收1.24亿美元，同比增长2.0%，归母净利润0.38亿美元，同比增长10.5%。
08-06 07:52
财报速睇 | ADMA Biologics 2026财年Q2营收1.24亿美元，同比增长2.0%；归母净利润0.38亿美元，同比增长10.5%
华盛资讯8月6日讯，ADMA Biologics公布2026财年Q2业绩，公司Q2营收1.24亿美元，同比增长2.0%，归母净利润0.38亿美元，同比增长10.5%。
08-06 05:40
